<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Pharmacol Exp Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Pharmacol. Exp. Ther</journal-id>
<journal-id journal-id-type="hwp">jpet</journal-id>
<journal-id journal-id-type="pmc">J Pharmacol Exp Ther</journal-id>
<journal-id journal-id-type="publisher-id">JPET</journal-id>
<journal-title-group>
<journal-title>The Journal of Pharmacology and Experimental Therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3565</issn>
<issn pub-type="epub">1521-0103</issn>
<publisher>
<publisher-name>The American Society for Pharmacology and Experimental Therapeutics</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26675679</article-id>
<article-id pub-id-type="pmc">4767398</article-id>
<article-id pub-id-type="publisher-id">JPET_230391</article-id>
<article-id pub-id-type="doi">10.1124/jpet.115.230391</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuropharmacology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>GluN2D <italic>N</italic>-Methyl-<sc>d</sc>-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for Schizophrenia<xref ref-type="fn" rid="FN3"><sup><inline-graphic xlink:href="sbox.jpg"></inline-graphic></sup></xref></article-title>
<alt-title alt-title-type="short">GluN2D-Dependent Actions of Ketamine</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sapkota</surname>
<given-names>Kiran</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3737-2900</contrib-id>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mao</surname>
<given-names>Zhihao</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Synowicki</surname>
<given-names>Paul</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lieber</surname>
<given-names>Dillon</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Meng</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ikezu</surname>
<given-names>Tsuneya</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gautam</surname>
<given-names>Vivek</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Monaghan</surname>
<given-names>Daniel T.</given-names>
</name>
</contrib>
<aff id="aff1">Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska (K.S., Z.M., P.S., D.L., M.L., D.T.M.); Departments of Pharmacology &amp; Experimental Therapeutics and Neurology, School of Medicine, Boston University, Boston, Massachusetts (T.I.); Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (V.G.)</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Address correspondence to:</bold> Dr. Daniel T. Monaghan, <addr-line>Department of Pharmacology and Experimental Neuroscience, 600 S. 42nd Street, Box 985800, Nebraska Medical Center, Omaha, NE 68198-5800.</addr-line> E-mail: <email>dtmonagh@unmc.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>3</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>356</volume>
<issue>3</issue>
<fpage>702</fpage>
<lpage>711</lpage>
<history>
<date date-type="received">
<day>02</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>12</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri xlink:href="jpet.115.230391.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<self-uri xlink:href="jpet.115.230391_thumb.jpg" xlink:role="icon" xlink:type="simple"></self-uri>
<abstract>
<p>The dissociative anesthetic ketamine elicits symptoms of schizophrenia at subanesthetic doses by blocking <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors (NMDARs). This property led to a variety of studies resulting in the now well-supported theory that hypofunction of NMDARs is responsible for many of the symptoms of schizophrenia. However, the roles played by specific NMDAR subunits in different symptom components are unknown. To evaluate the potential contribution of GluN2D NMDAR subunits to antagonist-induced cortical activation and schizophrenia symptoms, we determined the ability of ketamine to alter regional brain activity and gamma frequency band neuronal oscillations in wild-type (WT) and GluN2D-knockout (GluN2D-KO) mice. In WT mice, ketamine (30 mg/kg, i.p.) significantly increased [<sup>14</sup>C]-2-deoxyglucose ([<sup>14</sup>C]-2DG) uptake in the medial prefrontal cortex (mPFC), entorhinal cortex and other brain regions, and decreased activity in the somatosensory cortex and inferior colliculus. In GluN2D-KO mice, however, ketamine did not significantly increase [<sup>14</sup>C]-2DG uptake in any brain region examined, yet still decreased [<sup>14</sup>C]-2DG uptake in the somatosensory cortex and inferior colliculus. Ketamine also increased locomotor activity in WT mice but not in GluN2D-KO mice. In electrocorticographic analysis, ketamine induced a 111% ± 16% increase in cortical gamma-band oscillatory power in WT mice, but only a 15% ± 12% increase in GluN2D-KO mice. Consistent with GluN2D involvement in schizophrenia-related neurologic changes, GluN2D-KO mice displayed impaired spatial memory acquisition and reduced parvalbumin (PV)-immunopositive staining compared with control mice. These results suggest a critical role of GluN2D-containing NMDARs in neuronal oscillations and ketamine’s psychotomimetic, dissociative effects and hence suggests a critical role for GluN2D subunits in cognition and perception.</p>
</abstract>
<abstract abstract-type="graphical">
<p>
<fig fig-type="featured" id="absf1" position="float">
<graphic xlink:href="jpet.115.230391absf1"></graphic>
</fig>
</p>
</abstract>
<counts>
<page-count count="10"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name> DJS Export </meta-name>
<meta-value>v1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>